Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twelve analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $34.82.
Several research analysts have commented on RGNX shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a research report on Wednesday, January 15th. Raymond James restated an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a report on Thursday, October 10th. Finally, Morgan Stanley restated an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th.
Read Our Latest Stock Analysis on REGENXBIO
REGENXBIO Stock Performance
Institutional Investors Weigh In On REGENXBIO
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its holdings in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares in the last quarter. FMR LLC grew its holdings in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares in the last quarter. nVerses Capital LLC lifted its holdings in shares of REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 3,720 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in REGENXBIO during the third quarter worth $140,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Further Reading
- Five stocks we like better than REGENXBIO
- What is the Nasdaq? Complete Overview with History
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- How to Evaluate a Stock Before Buying
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.